Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.

Autor: Otsuki Y; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan., Yamasaki J; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan., Suina K; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan., Okazaki S; Division of Development and Aging, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan., Koike N; Department of Radiology, Keio University School of Medicine, Tokyo, Japan., Saya H; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan., Nagano O; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.

Publikováno v: Cancer science [Cancer Sci] 2020 Jan; Vol. 111 (1), pp. 127-136. Date of Electronic Publication: 2019 Nov 22.

Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions.

Autor: Wetzelsberger N; Institut für Klinische Pharmakologie Bobenheim, Grünstadt, Germany., Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D

Publikováno v: Methods and findings in experimental and clinical pharmacology [Methods Find Exp Clin Pharmacol] 1995 Apr; Vol. 17 (3), pp. 185-91.

[Ageusia as the aftereffect of oxyfedrine use].

Autor: Lantzsch W; I Kliniki i Polikliniki Medycyny Wewnetrznej, Halle-Wittenberg., Fikentscher R, Obrebowski A

Publikováno v: Otolaryngologia polska = The Polish otolaryngology [Otolaryngol Pol] 1991; Vol. 45 (2), pp. 148-50.

[Oxyfedrine in coronary therapy].

Autor: Wallner H, Sternitzke N, Schieffer H

Publikováno v: ZFA. Zeitschrift fur Allgemeinmedizin [ZFA (Stuttgart)] 1980 Mar 31; Vol. 56 (9 Suppl), pp. 612-6.

[Positive inotropic effect of coronary-active drug: oxyfedrine].

Autor: Conti G, Moreschini G, Pelosi M

Publikováno v: Minerva cardioangiologica [Minerva Cardioangiol] 1980 Sep; Vol. 28 (9), pp. 645-7.